WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Abroad (travel likely)RecruitingPHASE2

Conditions

Idiopathic Pulmonary Fibrosis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
Study leads
  • Todd Astor, MD

    Study Chair

    Mediar Therapeutics